CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 62 filers reported holding CYTOSORBENTS CORP in Q3 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,800 | -47.6% | 10,000 | 0.0% | 0.02% | -40.7% |
| Q2 2023 | $35,900 | +6.5% | 10,000 | 0.0% | 0.03% | +3.8% |
| Q1 2023 | $33,700 | +117.4% | 10,000 | 0.0% | 0.03% | +116.7% |
| Q4 2022 | $15,500 | +10.7% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $14,000 | -36.4% | 10,000 | 0.0% | 0.01% | -33.3% |
| Q2 2022 | $22,000 | -31.2% | 10,000 | 0.0% | 0.02% | -14.3% |
| Q1 2022 | $32,000 | -23.8% | 10,000 | 0.0% | 0.02% | -22.2% |
| Q4 2021 | $42,000 | -48.1% | 10,000 | 0.0% | 0.03% | -55.0% |
| Q3 2021 | $81,000 | +6.6% | 10,000 | 0.0% | 0.06% | +7.1% |
| Q2 2021 | $76,000 | -12.6% | 10,000 | 0.0% | 0.06% | -18.8% |
| Q1 2021 | $87,000 | +8.8% | 10,000 | 0.0% | 0.07% | 0.0% |
| Q4 2020 | $80,000 | 0.0% | 10,000 | 0.0% | 0.07% | -4.2% |
| Q3 2020 | $80,000 | -19.2% | 10,000 | 0.0% | 0.07% | -33.9% |
| Q2 2020 | $99,000 | +28.6% | 10,000 | 0.0% | 0.11% | +17.2% |
| Q1 2020 | $77,000 | +102.6% | 10,000 | 0.0% | 0.09% | +126.8% |
| Q4 2019 | $38,000 | – | 10,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skylands Capital, LLC | 1,772,000 | $13,379,000 | 1.58% |
| Sargent Investment Group, LLC | 856,315 | $6,465,000 | 1.53% |
| Avenir Corp | 1,366,549 | $10,317,000 | 0.82% |
| CM Management, LLC | 150,000 | $1,133,000 | 0.82% |
| Winning Points Advisors, LLC | 136,900 | $1,035,000 | 0.78% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 185,000 | $1,397,000 | 0.46% |
| SECTORAL ASSET MANAGEMENT INC | 244,660 | $1,847,000 | 0.15% |
| Redmile Group, LLC | 1,304,369 | $9,848,000 | 0.15% |
| Granahan Investment Management | 1,003,546 | $7,577,000 | 0.14% |
| ACT CAPITAL MANAGEMENT, LLC | 35,000 | $265,000 | 0.14% |